What is a biosimilar?
A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. When patients are prescribed a biological product, biosimilar and interchangeable products can offer additional treatment options, potentially lowering health care costs.
However, despite the health benefits of biosimilars, they are not yet widely available in the U.S. due to a variety of factors, including misinformation about the efficacy of biosimilars, efforts by some manufacturers to extend their patent protection, and rebates granted by some manufacturers to insurers and pharmacy benefit managers to cover biologics and not biosimilars.
We need policymakers to take action to increase access to biosimilars for patients living with chronic conditions. Sign up to tell legislators to cut health care costs by making biosimilars more accessible!
To whom it may concern:
As your constituent, I urge you to work with your fellow members to increase access to biosimilar products. Every day, low-income seniors and individuals with chronic conditions are making difficult choices to make ends meet. The lack of access to biosimilar drugs unnecessarily increases the burden on many of the most vulnerable members of society. Lifting restrictions and opening access to biosimilar products CHANGES that.
It's a solution that opens up market competition in the health care industry, potentially drives down health care costs, and alleviates the burden on some of the most vulnerable people in society. As a concerned constituent, I'm asking you to do something about this. It's clear that this is an issue that affects EVERYONE, not just seniors or the chronically ill. This issue can not be neglected any longer. I urge you to pass legislation opening access to biosimilar products. Lives are at stake here.
[Your comment here]
[Your name here]